Fig. 1: Pooled seroconversion rates following complete primary SARS-CoV-2 vaccination in patients with hematologic malignancies compared to those of healthy controls and patients with solid cancers. | Blood Cancer Journal

Fig. 1: Pooled seroconversion rates following complete primary SARS-CoV-2 vaccination in patients with hematologic malignancies compared to those of healthy controls and patients with solid cancers.

From: Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Fig. 1

Pooled seroconversion rates of hematologic malignancy patients with treatment and those without treatment were calculated from studies with disaggregated data on treatment.

Back to article page